Related references
Note: Only part of the references are listed.Levodopa/Carbidopa Intestinal Gel Long-Term Outcome in Parkinson's Disease: Focus on Dyskinesia
Margherita Fabbri et al.
MOVEMENT DISORDERS CLINICAL PRACTICE (2020)
Long-term safety and efficacy of 24-hour levodopa-carbidopa intestinal gel in Parkinson's disease
Hugo Morales-Briceno et al.
MOVEMENT DISORDERS (2019)
24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson's disease
Belinda Cruse et al.
NPJ PARKINSONS DISEASE (2018)
Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous L-DOPA delivery in the 6-OHDA model of Parkinson's disease
Giovanna Mulas et al.
EXPERIMENTAL NEUROLOGY (2016)
l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia
Hanna S. Lindgren et al.
JOURNAL OF NEUROCHEMISTRY (2010)
Share Paper
